Business ❯ Finance ❯ Stock Market

Pharmaceutical Stocks

Novo Nordisk Eli Lilly Pfizer Tariffs Market Reactions Market Performance Eli Lilly and Company Moderna AstraZeneca Vertex Pharmaceuticals

3 ARTICLES

5d ago

EMERALD-3 Trial Shows Progression-Free Survival Win for STRIDE Plus Lenvatinib With TACE

Investigators say the PFS benefit gives a rationale to test the STRIDE immunotherapy strategy earlier in treatment while overall survival continues to mature under follow-up.

5 ARTICLES

2w ago

Sacituzumab Tirumotecan With Keytruda Improves Progression-Free Survival in China Phase 3 Lung Cancer Trial

9 ARTICLES

2w ago

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

4 ARTICLES

3w ago

Inhibrx Combo Shows 44% Response vs 21% With Pembrolizumab Alone in First-Line Head and Neck Cancer

6 ARTICLES

4w ago

Cohance Lifesciences Shares Leap After Naming Umang Vohra Executive Chairman and Group CEO

4 ARTICLES

last mo.

Clearmind’s AUD Candidate Meets Early Safety Goal as Shares Double

6 ARTICLES

2mo ago

BullFrog AI Strikes Top-5 Pharma Deal To Find Depression Drug Targets

9 ARTICLES

2mo ago

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

6 ARTICLES

2mo ago

Kodiak’s Zenkuda Hits Phase 3 Goal in Diabetic Retinopathy Prompting Faster FDA Filing

4 ARTICLES

2mo ago

AIM ImmunoTech Secures Final Japan Patent for Ampligen Checkpoint-Inhibitor Cancer Therapy

8 ARTICLES

2mo ago

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

3 ARTICLES

3mo ago

Barclays Starts Merck at Overweight on 2026 Pipeline Catalysts as WSJ Reports Business Split Plan

3 ARTICLES

3mo ago

FDA Approves Vanda’s Bysanti for Bipolar I Mania and Schizophrenia

5 ARTICLES

4mo ago

Bristol Myers Gains Analyst Support as 2026 Catalysts Offset Patent-Cliff Worries

3 ARTICLES

4mo ago

Corvus Leaps After Soquelitinib Shows Strong Phase 1 Cohort 4 Eczema Data

Pharmaceutical Stocks

EMERALD-3 Trial Shows Progression-Free Survival Win for STRIDE Plus Lenvatinib With TACE

Sacituzumab Tirumotecan With Keytruda Improves Progression-Free Survival in China Phase 3 Lung Cancer Trial

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

Inhibrx Combo Shows 44% Response vs 21% With Pembrolizumab Alone in First-Line Head and Neck Cancer

Analysts Lift Eli Lilly Targets After Blowout Quarter and Foundayo Debut

Vertex Posts Mixed Quarter as Profit Beats, Sales Miss and Outlook Holds

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

Lilly’s Foundayo Start Trails Wegovy as Street Stays Positive

Erasca Shares Plunge After Trial Death and Patent Challenge

Cohance Lifesciences Shares Leap After Naming Umang Vohra Executive Chairman and Group CEO

Never miss stories about

Pharmaceutical Stocks

Clearmind’s AUD Candidate Meets Early Safety Goal as Shares Double

BullFrog AI Strikes Top-5 Pharma Deal To Find Depression Drug Targets

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

Kodiak’s Zenkuda Hits Phase 3 Goal in Diabetic Retinopathy Prompting Faster FDA Filing

AIM ImmunoTech Secures Final Japan Patent for Ampligen Checkpoint-Inhibitor Cancer Therapy

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

Barclays Starts Merck at Overweight on 2026 Pipeline Catalysts as WSJ Reports Business Split Plan

FDA Approves Vanda’s Bysanti for Bipolar I Mania and Schizophrenia

Bristol Myers Gains Analyst Support as 2026 Catalysts Offset Patent-Cliff Worries

Corvus Leaps After Soquelitinib Shows Strong Phase 1 Cohort 4 Eczema Data

Never miss stories about

Pharmaceutical Stocks